Nautical Chart Adequacy Evaluation Using Publicly-Available Data

The International Hydrographic Office (IHO) C-55 publication communicates the need to improve the collection, quality and availability of hydrographic data world-wide, while also monitoring and rectifying possible deficiencies and shortcomings that are presented on the chart. This task of evaluating the adequacy of nautical chart products poses a challenge to many national hydrographic offices. This stems from the dearth of readily available spatial information: namely, the lack of reliable and accessible vessel traffic data, and little means to assess the changing nature of both near-shore bathymetry and shoreline in a simple and reliable manner. In this paper, we present the potential use of automatic-identification system (AIS) data, satellite-derived bathymetry (SDB), and airborne-lidar bathymetry (ALB) to provide an operational procedure for evaluating the adequacy and completeness of information of NOAA charts. Preliminary results from three U.S. study sites are presented in this paper: Nantucket Sound, MA; Barnegat Bay Inlet, NJ; and Barataria Bay, LA. Based on the publically-available datasets it was possible to identify changes in the charts and develop a reconnaissance procedure to monitor these changes on a yearly basis

Companies face special challenges when employee departures pick up speed

Firms need to track turnover volatility as much as turnover rates, write Matthew Call, Anthony Nyberg and Rob Ployhar

The Chief HR Officer’s Role in CEO Succession: The View from the Board

Interviews with 22 members of public and private company boards revealed their beliefs about and expectations for CHROs in the Chief Executive Officer (CEO) succession process. Board members distinguished between credible CHROs who can add significant value to the process and those CHROs who they do not want to see included in almost any aspect of the process. When credible, board members want CHROs to have confidential conversations with the current CEO, to create processes and development plans for potential successors, and to provide their own independent insights regarding candidate strengths and weaknesses. Directors noted that CHROs who add value must display expertise, honesty, transparency, courage, and the ability to build trusting relationships

Leading through paradox in a Covid-19 world: human resources comes of age

The impact of the coronavirus disease (COVID‐19) pandemic is unprecedented. At an organisational level, the crisis has been hugely disruptive, complex and fraught with ambiguity for leaders. The crisis is fundamentally a human one, making human resource (HR) leaders central in enabling organisations to manage through and ultimately exit the crisis successfully. We apply a paradox lens to understand the HR leadership challenges posed by the COVID‐19 crisis. We argue that how the HR function responds to the challenges ofthe crisis and its role in mapping the exit route from the crisis are likely to shape the trajectory of the function for decades to come. The pandemic creates an unprecedented opportunity to elevate the status of the HR function in organisations where it has struggled to gain status and to reinforce the influence of the function in those where it already enjoys legitimacy. The value of this is likely to be reflected in more sustainable performance through the alignment of people and purpose and balancing the short and long term objectives of the organisatio

Evaluation of rangeland condition in miombo woodlands in eastern Tanzania in relation to season and distance from settlements

Miombo woodlands sustainability in east and south-central Africa is threatened by human activities, including overgrazing. This study investigated seasonal variations in rangeland condition in three grazed areas in miombo woodlands in eastern Tanzania. Transect lines were established across the grazing areas, sampling points were identified and marked at every 10% of the length of transect line. Sampling points were categorised in different distances with respect to settlement. The line intercept method was used to collect data on vegetation cover and forage distribution, while herbaceous forage biomass was estimated using a disc pasture meter. A total of 118 different plant species were observed and grasses comprised 40.6% of all herbaceous species. Bothriochloa pertusa, Cynodon plectostachyus, Hyparrhenia rufa and Urochloa mosambicensis grass species dominated miombo grazed areas in various seasons and distances. These perennial grass species are desirable and indicated moderate grazing activities in miombo. Season affected grass cover, herbaceous forage biomass and nutritional composition. Grass cover and forage biomass were at the lowest during late dry season while forage nutritional quality was best during early dry season. Distance from settlement had no effect on grass cover and herbaceous forage biomass. Rangeland condition was generally fair, livestock stocking rate in continuously grazed drylands should be set at the lowest monthly forage biomass in order to ensure grazing land sustainability

Renin-angiotensin system blockers and susceptibility to COVID-19:an international, open science, cohort analysis

Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been postulated to affect susceptibility to COVID-19. Observational studies so far have lacked rigorous ascertainment adjustment and international generalisability. We aimed to determine whether use of ACEIs or ARBs is associated with an increased susceptibility to COVID-19 in patients with hypertension.Methods: In this international, open science, cohort analysis, we used electronic health records from Spain (Information Systems for Research in Primary Care [SIDIAP]) and the USA (Columbia University Irving Medical Center data warehouse [CUIMC] and Department of Veterans Affairs Observational Medical Outcomes Partnership [VA-OMOP]) to identify patients aged 18 years or older with at least one prescription for ACEIs and ARBs (target cohort) or calcium channel blockers (CCBs) and thiazide or thiazide-like diuretics (THZs; comparator cohort) between Nov 1, 2019, and Jan 31, 2020. Users were defined separately as receiving either monotherapy with these four drug classes, or monotherapy or combination therapy (combination use) with other antihypertensive medications. We assessed four outcomes: COVID-19 diagnosis; hospital admission with COVID-19; hospital admission with pneumonia; and hospital admission with pneumonia, acute respiratory distress syndrome, acute kidney injury, or sepsis. We built large-scale propensity score methods derived through a data-driven approach and negative control experiments across ten pairwise comparisons, with results meta-analysed to generate 1280 study effects. For each study effect, we did negative control outcome experiments using a possible 123 controls identified through a data-rich algorithm. This process used a set of predefined baseline patient characteristics to provide the most accurate prediction of treatment and balance among patient cohorts across characteristics. The study is registered with the EU Post-Authorisation Studies register, EUPAS35296.Findings: Among 1 355 349 antihypertensive users (363 785 ACEI or ARB monotherapy users, 248 915 CCB or THZ monotherapy users, 711 799 ACEI or ARB combination users, and 473 076 CCB or THZ combination users) included in analyses, no association was observed between COVID-19 diagnosis and exposure to ACEI or ARB monotherapy versus CCB or THZ monotherapy (calibrated hazard ratio [HR] 0·98, 95% CI 0·84-1·14) or combination use exposure (1·01, 0·90-1·15). ACEIs alone similarly showed no relative risk difference when compared with CCB or THZ monotherapy (HR 0·91, 95% CI 0·68-1·21; with heterogeneity of &gt;40%) or combination use (0·95, 0·83-1·07). Directly comparing ACEIs with ARBs demonstrated a moderately lower risk with ACEIs, which was significant with combination use (HR 0·88, 95% CI 0·79-0·99) and non-significant for monotherapy (0·85, 0·69-1·05). We observed no significant difference between drug classes for risk of hospital admission with COVID-19, hospital admission with pneumonia, or hospital admission with pneumonia, acute respiratory distress syndrome, acute kidney injury, or sepsis across all comparisons.Interpretation: No clinically significant increased risk of COVID-19 diagnosis or hospital admission-related outcomes associated with ACEI or ARB use was observed, suggesting users should not discontinue or change their treatment to decrease their risk of COVID-19.</p

Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom

Altres ajuts: This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Center (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. The University of Oxford received funding related to this work from the Bill & Melinda Gates Foundation (Investment ID INV016201 and INV-019257). APU has received funding from the Medical Research Council (MRC) [MR/K501256/1, MR/N013468/1] and Fundación Alfonso Martín Escudero (FAME) (APU). VINCI [VA HSR RES 13-457] (SLD, MEM, KEL). JCEL has received funding from the Medical Research Council (MR/K501256/1) and Versus Arthritis (21605). MR is funded by Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant program [grant number: 2017/1630]A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity. We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status. We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8−40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0−33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity. We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies